Disease Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Effectiveness and Value
Draft Questions for Deliberation: February 16, 2017 Public Meeting

Relapsing-Remitting Multiple Sclerosis: Clinical Evidence

Oral Agents

1. For patients with RRMS, is the evidence adequate to demonstrate that the net health benefit of *dimethyl fumarate* (*Tecfidera*®, *Biogen Inc.* ) is greater than that of *fingolimod* (*Gilenya*®, *Novartis, Inc.*)?
   Yes No

2. For patients with RRMS, is the evidence adequate to demonstrate that the net health benefit of *dimethyl fumarate* is greater than that or *teriflunomide 14 mg* (*Aubagio*®, *Sanofi-Regeneron, Inc.*)?
   Yes No

3. For patients with RRMS, is the evidence adequate to demonstrate that the net health benefit of *fingolimod* is greater than that or *teriflunomide 14 mg*?
   Yes No

Emerging Agents

4. For patients with RRMS, is the evidence adequate to demonstrate that the net health benefit of *daclizumab* (*Zinbryta™, Biogen Inc.*) is greater than that of *dimethyl fumarate or fingolimod*?
   Yes No

5. For patients with RRMS, is the evidence adequate to demonstrate that the net health benefit of *daclizumab* is greater than that of *generic glatiramer acetate 20 mg* (*Glatopa*, *Sandoz, Inc.*)?
   Yes No

6. For patients with RRMS, is the evidence adequate to demonstrate that the net health benefit of *ocrelizumab* (*Ocrevus*, *Roche Genentech Inc.*) is greater than that of *generic glatiramer acetate 20 mg*?
   Yes No
7. For patients with RRMS, is the evidence adequate to demonstrate that that the *net health benefit* of treatment with *interferon beta-1a 44 mcg (Rebif®, EMD Serono Inc.)* is greater than that of treatment with *interferon beta-1a 30 mcg (Avonex®, Biogen Inc.)*?
   Yes  No

Relapsing-Remitting Multiple Sclerosis: Long-term Value for Money

8. Given the available evidence for patients with RRMS, what is the *long-term value for money* of treatment with *daclizumab* versus treatment with *generic glatiramer acetate 20 mg*?
   a. Low  b. Intermediate  c. High

9. Given the available evidence for patients with RRMS, what is the *long-term value for money* of the treatment with *ocrelizumab* versus treatment with *generic glatiramer acetate 20 mg*?
   a. Low  b. Intermediate  c. High

Primary Progressive Multiple Sclerosis: Clinical Evidence

10. For patients with primary progressive multiple sclerosis (PPMS), is the evidence adequate to demonstrate that the *net health benefit* of treatment with *ocrelizumab* is greater than that of *best supportive care*?
    Yes  No

Primary Progressive Multiple Sclerosis: Long-term Value for Money

11. Given the available evidence for patients with PPMS, what is the *long-term value for money* of treatment with *ocrelizumab* versus *best supportive care*?
    a. Low  b. Intermediate  c. High